|Bid||58.52 x 800|
|Ask||58.66 x 800|
|Day's Range||58.53 - 60.49|
|52 Week Range||38.41 - 79.92|
|Beta (5Y Monthly)||0.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2023 - Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||83.22|
IRVINE, Calif., January 31, 2023--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation system.
Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
We feel now is a pretty good time to analyse Axonics, Inc.'s ( NASDAQ:AXNX ) business as it appears the company may be...